{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:11:24Z","timestamp":1793257884068,"version":"4.5.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI106398-01"],"award-info":[{"award-number":["R01AI106398-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI111967"],"award-info":[{"award-number":["R01AI111967"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1066499"],"award-info":[{"award-number":["OPP1066499"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1031105"],"award-info":[{"award-number":["OPP1031105"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["37882"],"award-info":[{"award-number":["37882"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["077381"],"award-info":[{"award-number":["077381"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002773","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T13:23:46Z","timestamp":1554211426000},"page":"e1002773","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":193,"title":["Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-0783","authenticated-orcid":true,"given":"Natasha","family":"Strydom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha V.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-4333","authenticated-orcid":true,"given":"William S.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Via","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeeun","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-1807","authenticated-orcid":true,"given":"Myungsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokyong","family":"Eum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-816X","authenticated-orcid":true,"given":"TaeSun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-270X","authenticated-orcid":true,"given":"Clifton E.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-5009","authenticated-orcid":true,"given":"V\u00e9ronique","family":"Dartois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":true,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"ref1","article-title":"Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments","year":"2018"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","volume":"371","author":"A Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","volume":"371","author":"SH Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis","volume":"371","author":"CS Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"CE Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"V. Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"B Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12918-015-0221-8","article-title":"In silico evaluation and exploration of antibiotic tuberculosis treatment regimens","volume":"9","author":"E Pienaar","year":"2015","journal-title":"BMC Syst Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"eaai7786","DOI":"10.1126\/scitranslmed.aai7786","article-title":"Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data","volume":"10","author":"D Rifat","year":"2018","journal-title":"Sci Transl Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials","volume":"102","author":"R Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"DR Mould","year":"2013","journal-title":"CPT pharmacometrics Syst Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"RM Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"MC Kjellsson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.32614\/CRAN.package.xpose","article-title":"xpose: Diagnostics for Pharmacometric Models","author":"B Guiastrennec","year":"2017"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"T. Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","unstructured":"EUCAST. EUCAST. In: EUCAST [Internet]. 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eucast.org\/ast_of_bacteria\/\" xlink:type=\"simple\">http:\/\/www.eucast.org\/ast_of_bacteria\/<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref17","unstructured":"Lavielle M. mlxR: Simulation of Longitudinal Data [Internet]. 2017. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cran.r-project.org\/package=mlxR\" xlink:type=\"simple\">https:\/\/cran.r-project.org\/package=mlxR<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref18","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2017. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.r-project.org\/\" xlink:type=\"simple\">https:\/\/www.r-project.org\/<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref19","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA; 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.rstudio.com\/\" xlink:type=\"simple\">http:\/\/www.rstudio.com\/<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref20","unstructured":"Chang W, Cheng J, Allaire JJ, Xie Y, McPherson J. shiny: Web Application Framework for R [Internet]. 2017. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cran.r-project.org\/package=shiny\" xlink:type=\"simple\">https:\/\/cran.r-project.org\/package=shiny<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/17410541.4.2.123","article-title":"NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients","volume":"4","author":"CJ Werely","year":"2007","journal-title":"Per Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum","volume":"62","author":"JP Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.01370-15","article-title":"Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB\/FeJ Mice Is Best Explained by Neutral pH of Caseum","volume":"60","author":"J-P Lanoix","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.02565-14","article-title":"Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas","volume":"58","author":"SM Irwin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"R Jayaram","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"SB Lakshminarayana","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"AD Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid","volume":"58","author":"LM Boak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum","volume":"62","author":"JP Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jac\/dkx421","article-title":"Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study","volume":"73","author":"MT Heinrichs","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","volume":"371","author":"A Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","volume":"371","author":"SH Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e00139-10","DOI":"10.1128\/mBio.00139-10","article-title":"The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model","volume":"1","author":"GL Drusano","year":"2010","journal-title":"MBio"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1128\/AAC.00554-08","article-title":"Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations","volume":"52","author":"K Dooley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"A Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref36","article-title":"Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)","year":"2018"},{"key":"ref37","unstructured":"Conradie F, Diacon AH, Everitt D, Mendel CM, van Niekerk C, Howell P, et al. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. Oral presentation at 49th World Conference on lung health of the International Union against tuberculosis and lung disease (The Union) October 25, 2018, The Hague, The Netherlands. The Hague; 2018. p. S69. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.abstractserver.com\/TheUnion2018\/TheUnion2018_Abstracts_Web.pdf\" xlink:type=\"simple\">https:\/\/www.abstractserver.com\/TheUnion2018\/TheUnion2018_Abstracts_Web.pdf<\/ext-link> (Accessed March 18, 2019)"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1715849","article-title":"Bacterial Factors That Predict Relapse after Tuberculosis Therapy","volume":"379","author":"R Colangeli","year":"2018","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"MZ Imperial","year":"2018","journal-title":"Nat Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40001-016-0214-0","article-title":"The value of initial cavitation to predict re-treatment with pulmonary tuberculosis","volume":"21","author":"Q Huang","year":"2016","journal-title":"Eur J Med Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1128\/IAI.71.12.7099-7108.2003","article-title":"Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity","volume":"71","author":"G Kaplan","year":"2003","journal-title":"Infect Immun"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/cir904","article-title":"Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis","volume":"54","author":"RR Kempker","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41115","article-title":"High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types","volume":"7","author":"L Blanc","year":"2018","journal-title":"Elife"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in <italic>Mycobacterium tuberculosis<\/italic> Infected C3HeB\/FeJ Mice","volume":"2","author":"SM Irwin","year":"2016","journal-title":"ACS Infect Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of Drug Penetration in Tuberculosis Lesions","volume":"2","author":"JP Sarathy","year":"2016","journal-title":"ACS Infect Dis"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:44:41Z","timestamp":1721126681000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002773"}},"subtitle":[],"editor":[{"given":"Megan","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002773","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}